Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Trevi Therapeutics Inc (TRVI)

Trevi Therapeutics Inc (TRVI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,637,497
  • Shares Outstanding, K 128,230
  • Annual Sales, $ 0 K
  • Annual Income, $ -47,910 K
  • EBIT $ -51 M
  • EBITDA $ -51 M
  • 60-Month Beta 0.83
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 8.45

Options Overview Details

View History
  • Implied Volatility 98.74% (-41.95%)
  • Historical Volatility 72.15%
  • IV Percentile 50%
  • IV Rank 9.09%
  • IV High 609.07% on 01/30/25
  • IV Low 47.69% on 08/22/25
  • Expected Move (DTE 5) 2.08 (16.31%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1,141
  • Volume Avg (30-Day) 802
  • Put/Call OI Ratio 0.55
  • Today's Open Interest 25,089
  • Open Int (30-Day) 23,822
  • Expected Range 10.69 to 14.85

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.10
  • Number of Estimates 7
  • High Estimate -0.08
  • Low Estimate -0.12
  • Prior Year -0.11
  • Growth Rate Est. (year over year) +9.09%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.46 +22.08%
on 11/21/25
14.39 -11.26%
on 12/10/25
+0.92 (+7.76%)
since 11/12/25
3-Month
7.64 +67.04%
on 09/15/25
14.39 -11.26%
on 12/10/25
+4.52 (+54.79%)
since 09/12/25
52-Week
3.47 +267.85%
on 01/22/25
14.39 -11.26%
on 12/10/25
+9.17 (+254.72%)
since 12/12/24

Most Recent Stories

More News
Trevi Therapeutics Announces Appointment of David Hastings as Chief Financial Officer

Experienced biotech CFO to lead financial strategy and contribute to the Company's next stage of growth

TRVI : 12.77 (-3.04%)
Trevi Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates

Company preparing to initiate comprehensive Phase 3 program for chronic cough in patients with idiopathic pulmonary fibrosis in first half of 2026

TRVI : 12.77 (-3.04%)
Trevi Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 13, 2025

Conference call and webcast to be held at 4:30 p.m. ET

TRVI : 12.77 (-3.04%)
Trevi Therapeutics to Participate in Stifel 2025 Healthcare Conference

Fireside Chat with Management on Tuesday, November 11, 2025, at 3:20 p.m. ET

TRVI : 12.77 (-3.04%)
Trevi Therapeutics Completes Key Phase 1 Drug Interaction Study

Trevi Therapeutics ((TRVI)) announced an update on their ongoing clinical study.Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced...

TRVI : 12.77 (-3.04%)
Trevi Therapeutics Announces Oral Presentation and Abstracts at CHEST 2025 Annual Meeting

Professor Philip Molyneaux will give an oral presentation on the key efficacy and safety results from the Phase 2b CORAL trial of nalbuphine ER for the treatment of chronic cough in patients with idiopathic...

TRVI : 12.77 (-3.04%)
Analysts Are Bullish on Top Healthcare Stocks: MoonLake Immunotherapeutics (MLTX), Trevi Therapeutics (TRVI)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on MoonLake Immunotherapeutics (MLTX – Research Report), Trevi Therapeutics (TRVI – Research Report) and...

ANVS : 4.13 (+8.97%)
TRVI : 12.77 (-3.04%)
MLTX : 14.79 (+5.12%)
Trevi Therapeutics (TRVI) Receives a Buy from Leerink Partners

Leerink Partners analyst Faisal Khurshid reiterated a Buy rating on Trevi Therapeutics on September 29. The company’s shares closed yesterday at $9.56.Elevate Your Investing Strategy: Take advantage...

TRVI : 12.77 (-3.04%)
Trevi Therapeutics Announces Two Posters from the Phase 2a RIVER Trial Data Will be Featured at the European Respiratory Society (ERS) Congress 2025

NEW HAVEN, Conn. , Sept. 18, 2025 /PRNewswire/ --  Trevi Therapeutics, Inc.  (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™...

TRVI : 12.77 (-3.04%)
Trevi Therapeutics to Participate in Upcoming September Conferences

NEW HAVEN, Conn. , Aug. 28, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc.  (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™...

TRVI : 12.77 (-3.04%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Trevi Therapeutics Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. The company is currently developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in...

See More

Key Turning Points

3rd Resistance Point 13.99
2nd Resistance Point 13.72
1st Resistance Point 13.24
Last Price 12.77
1st Support Level 12.50
2nd Support Level 12.23
3rd Support Level 11.76

See More

52-Week High 14.39
Last Price 12.77
Fibonacci 61.8% 10.22
Fibonacci 50% 8.93
Fibonacci 38.2% 7.64
52-Week Low 3.47

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar